Estrella Immunopharma, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ESLA research report →
Companywww.estrellabio.com
Estrella Immunopharma, Inc. , a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia.
- CEO
- Cheng Liu
- IPO
- 2021
- Employees
- 3
- HQ
- EmeryVille, CA, US
Price Chart
Valuation
- Market Cap
- $47.77M
- P/E
- -3.53
- P/S
- 0.00
- P/B
- -8.87
- EV/EBITDA
- -3.46
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 167.91%
- ROIC
- 251.42%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-13,063,512 · -47.65%
- EPS
- $-0.35 · -40.00%
- Op Income
- $-13,062,674
- FCF YoY
- 76.63%
Performance & Tape
- 52W High
- $3.15
- 52W Low
- $0.78
- 50D MA
- $1.38
- 200D MA
- $1.42
- Beta
- 0.98
- Avg Volume
- 86.87K
Get TickerSpark's AI analysis on ESLA
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 7, 25 | Xu Jiandong | buy | 1,000 |
| Sep 11, 25 | Xu Jiandong | buy | 100 |
| Sep 22, 25 | Xu Jiandong | buy | 1,000 |
| Sep 22, 25 | Jia Dengyao | other | 0 |
| Oct 30, 24 | Liu Cheng | other | 509,204 |
| Oct 30, 24 | Liu Cheng | other | 490,796 |
| Oct 30, 24 | Xu Jiandong | other | 509,204 |
| Oct 30, 24 | Xu Jiandong | other | 490,796 |
| Aug 14, 24 | Zhang Hong | other | 0 |
| Sep 29, 23 | Xu Jiandong | other | 0 |
Our ESLA Coverage
We haven't published any research on ESLA yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate ESLA Report →